Dr. Kenneth Lindahl is the first Ophthalmologist in the greater Rochester area to offer the newest, FDA approved Trifocal Intraocular Lens (IOL) for cataract patients, the AcrySof IQ PanOptix Trifocal IOL.
What's an IOL? Learn more here.
PanOptix is already one of the leading presbyopia-correcting IOLs in more than 70 countries, but has only been FDA approved in the US since 2019. It is designed for today’s active lifestyles, from viewing mobile devices and computer screens to high-quality distance vision in a range of lighting conditions.
The new lens uses ENLIGHTEN® Optical Technology, a proprietary design that optimizes intermediate vision without compromising near and distance vision. Available in spherical and toric designs, PanOptix is built on Alcon’s proven AcrySof IQ IOL platform that has been implanted in more than 120 million eyes globally.
“We are proud to bring this new class of IOLs to the largest eye care market in the world,” said David J. Endicott, Chief Executive Officer of Alcon. “We are leveraging Alcon’s years of experience with PanOptix in other countries to provide the best possible training and support for U.S. surgeons. Our goal is to ensure optimal outcomes for cataract patients looking to correct their vision at all distances, with the vast majority of them never needing to wear glasses post-surgery.”
The FDA approval of PanOptix was based on a pivotal study at 12 investigational sites in the U.S. With this single trifocal lens design, PanOptix patients demonstrated exceptional, uninterrupted vision. The results also showed high patient satisfaction with more than ninety-nine percent of PanOptix patients saying they would choose the same lens again.
More than 4 million cataract surgeries are performed each year in the U.S., which is projected to increase by more than 16 percent by the end of 2024.3,4 The presbyopia-correcting IOL market is expected to grow 60 percent by the end of 2024.
“The U.S. ophthalmology community has been eagerly awaiting FDA approval of PanOptix, said Kenneth Lindahl, M.D., Rochester Eye and Laser Center owner, Ophthalmologist. “We know patients undergoing cataract surgery today want a replacement lens that delivers the vision they need to live full, active lives without always being dependent on glasses. PanOptix is an excellent lens option to address these needs and is clinically proven to deliver an outstanding range of vision.”
About Rochester Eye and Laser Center
Rochester Eye & Laser Center has served Rochester’s vision care needs since 1988. Your eye care professionals are all in one, friendly East End office. No shuttling around Rochester from optometrist to optician to ophthalmologist.
Dr. Lindahl personally meets and cares for every patient through the entire surgical process and for all eye care needs.
The Rochester Eye & Laser Team : Jul 20, 2022 9:27:23 AM
{% video_player "embed_player" overrideable=False, type='hsvideo2', hide_playlist=True, viral_sharing=False, embed_button=False, autoplay=False,...
The Rochester Eye & Laser Team : Jul 26, 2022 4:33:48 PM
One certainty in life is that everyone will eventually develop cataracts. In fact, cataract formation starts earlier than you might think,...
The Rochester Eye & Laser Team : Jun 23, 2021 3:05:29 PM
PanOptix® Trifocal Intraocular Lens (IOL), the first and only trifocal lens for U.S. patients undergoing cataract surgery. PanOptix is clinically...
The Rochester Eye & Laser Team